Compare Nomura Holdings Inc (NMR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Nomura Holdings Inc trades at $9.2 (market cap $28.01B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Nomura Holdings Inc is far larger — about 3.7× Spyre Therapeutics Inc. Common Stock's market cap, and Nomura Holdings Inc pays a 3.38% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 56 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NMR | SYRE | |
|---|---|---|
Market Cap | $28.01B | $7.52B |
Volume | 686,801 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $10.86 | $108.92 |
52-Week Low | $6.92 | $22.18 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $38.48T | $6.52B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.26, down 3.24% with bearish technical signals. The stock shows mixed earnings performance with recent misses but strong revenue growth from $1.66T in 2025. Valuation appears attractive with P/E of 11.37 and P/B of 1.16, while analyst sentiment leans cautious with 67% hold ratings. Recent Zacks coverage highlights momentum potential and hammer chart pattern formation.
Outlook remains balanced with fundamental strength in profitability margins (20.4% net income) offset by technical weakness. Investment opportunity lies in discounted valuation amid earnings growth, while risks include cash flow volatility and rising debt levels. The stock requires careful monitoring of Q3 2026 earnings results for directional clarity.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
